Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen recep
Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy- also pioneered at Penn- for solid cancer tumors and offers a promising new strategy in the fight against cancer.
Milwaukee, WI (PRWEB) November 01, 2021 The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2021,
BRCA variants, results of a small phase II trial showed.
A patient cohort with germline and somatic mutations, including
PALB2, had a 6-month progression-free survival (PFS) of 59.5%, decreasing only slightly to 54.5% at 12 months with maintenance rucaparib (Rubraca). The overall response rate of 41.7% included patients with germline (g) and somatic (s)
BRCA1/2 mutations and those with
PALB2 variants. Two-thirds of patients obtained disease control with the PARP inhibitor, according to Kim A. Reiss, MD, of University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues.
The results supported and extended those from the practicing-changing POLO trial of olaparib (Lynparza) maintenance for g